Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
M Gabriela Cabanilla, Michael L. Bernauer, Liana M. Atallah, Matthew J. Briski, Jason Koury, Cecilia M. Thompson, Chelsea N. Rodriguez, Bernadette Jakeman, Thomas F. Byrd
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Predictors of mortality in Staphylococcus aureus bacteremia
2021
Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study
10.1086/421946 · 2004
A comparison of long-term outcomes after meticillin-resistant and meticillin-sensitive Staphylococcus aureus bactaraemia: an observational cohort study
10.1016/s1473-3099(14)70876-x · 2014
Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus
10.1001/archinte.162.19.2229 · 2002
Unresolved referenced work
Kept as external metadata until matched
Persistent Staphylococcus aureus bacteremia
10.1097/md.0b013e318289ff1e · 2013
Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children
10.1093/cid/ciq146 · 2011
Defining persistent Staphylococcus aureus bacteremia: secondary analysis of a prospective cohort study
10.1016/s1473-3099(20)30447-3 · 2020
Effect of vancomycin or daptomycin with vs without antistaphylococcal beta-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial
10.1001/jama.2020.0103 · 2020
Unresolved referenced work
Kept as external metadata until matched
Persistent methicillin-resistant Staphylococcus aureus bacteremia: resetting the clock for optimal management
10.1093/cid/ciac364 · 2022
Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome
10.1080/00365540500372846 · 2006
Predictors of persistent methicillin-resistant staphylococcus aureus bacteraemia in patients treated with vancomycin
10.1093/jac/dkq050 · 2010
Beta-lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone
10.1128/aac.01204-13 · 2014
Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia
10.1128/aac.02483-18 · 2019
Early Administration of Adjuvant β-Lactam Therapy in Combination with Vancomycin among Patients with Methicillin-Resistant Staphylococcus aureus Bloodstream Infection: A Retrospective, Multicenter Analysis
10.1002/phar.2034 · 2017
Daptomycin plus beta lactam combination therapy for methicillin-resistant Staphylococcus aureus bloodstream infections: a retrospective, comparative cohort study
10.1093/cid/ciz746 · 2020
Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline
10.1016/j.clinthera.2014.05.061 · 2014
Ceftaroline for severe methicillin-resistant Staphylococcus aureus infections: a systematic review
10.1093/ofid/ofx084 · 2017
Ceftaroline as salvage monotherapy for persistent MRSA bacteremia
10.1177/1060028016664361 · 2016
Vancomycin plus ceftaroline for persistent methicillin-resistant Staphylococcus aureus bacteremia
10.1002/phar.2741 · 2023
Outcomes of daptomycin plus ceftaroline versus alternative therapy for persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia
10.1016/j.ijantimicag.2023.106735 · 2023
Role of comorbidity in mortality related to Staphylococcus aureus bacteremia: a prospective study using the Charlson weighted index of comorbidity
10.1086/502156 · 2003
Staphylococcus aureus bacteremia: predictors of 30-day mortality in a large cohort
10.1086/317421 · 2000
Risk factors of treatment failure and 30-day mortality in patients with bacteremia due to MRSA with reduced vancomycin susceptibility
10.1038/s41598-018-26277-9 · 2018
Risk factors for 30-day mortality in patients with methicillin-resistant Staphylococcus aureus bloodstream infections
10.1016/j.ijid.2017.05.010 · 2017
Multicenter cohort of patients with methicillin-resistant Staphylococcus aureus bacteremia receiving daptomycin plus ceftaroline compared with other MRSA treatments
10.1093/ofid/ofz538 · 2020
Combination of vancomycin and beta-lactam therapy for MRSA bacteremia: a pilot multicenter randomized controlled trial
10.1093/cid/civ808 · 2016
Monotherapy with vancomycin or daptomycin versus combination therapy with beta-lactams in the treatment of methicillin-resistant Staphylococcus aureus bloodstream infections: a retrospective cohort analysis
10.1007/s40121-020-00292-8 · 2020
Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary
10.1093/cid/cir034 · 2011
Persistent methicillin-resistant staphylococcus aureus bacteremia: host, pathogen, and treatment
10.3390/antibiotics12030455 · 2023
Incidence, prevalence, and management of MRSA bacteremia across patient populations–a review of recent developments in MRSA management and treatment
10.1186/s13054-017-1801-3 · 2017
Daptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant Staphylococcus aureus bacteremia and endocarditis, a randomized clinical trial
10.1093/cid/ciaa1081 · 2021
No additional external references are available.